Sandoz, the generic drugs business that will be spun off its parent Novartis, will boost investment in its European antibiotics production network by 50 million euros ($50 million) on strong global demand for bacteria-fighting medicines.
https://www.pharmalive.com/wp-content/uploads/2021/12/Novartis-working-on-pan-coronavirus-oral-treatment-CEO-says-Reuters-12-6-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-11-07 08:48:252022-11-07 09:52:07Novartis adds 50 million euros to European antibiotics investment budget
